Effects of a Combined Treatment With GPR30 Agonist G-1 and Herceptin on Growth and Gene Expression of Human Breast Cancer Cell Lines

REFERENCES

• Beeghly-Fadiel A, Kataoka N, Shu XO, Cai Q, Deming SL, Gao YT, Zheng W. Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study. Oncol Rep 2008;19(5):1347–1354.
   PubMed Web of Science ®Google Scholar
• Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116(12):2856–2867.
   PubMed Web of Science ®Google Scholar
• Hayashida T, Jinno H, Sakata M, Takahashi M, Kitagawa Y. Current strategies of primary therapy for breast cancer. Nippon Rinsho 2010;68(6):1137–1142.
   PubMedGoogle Scholar
• Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. Expert Opin Biol Ther 2010;10(5):711–721.
   PubMed Web of Science ®Google Scholar
• Wren BG. The origin of breast cancer. Menopause 2007; 14(6):1060–1068.
   PubMed Web of Science ®Google Scholar
• Welboren WJ, Sweep FC, Span PN, Stunnenberg HG. Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer 2009;16(4):1073–1089.
   PubMed Web of Science ®Google Scholar
• Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Andò S, Maggiolini M. G protein coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007;67(4):1859–1866.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor GPR30 with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 2008;73(9–10):870–873.
   PubMed Web of Science ®Google Scholar
• Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C. A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010;75(8–9):603–610.
   PubMed Web of Science ®Google Scholar
• Otto C, Rohde-Schulz B, Schwarz G, Fuchs I, Klewer M, Brittain D, Langer G, Bader B, Prelle K, Nubbemeyer R, Fritzemeier KH. G protein-coupled receptor 30 localizes to the endoplasmatic reticulum and is not activated by estradiol. Endocrinology 2008;149(10):4846–4856.
   PubMed Web of Science ®Google Scholar
• Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2(4):175–176.
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G protein-coupled receptor GPR30. Annu Rev Physiol 2008;70:165–190.
   PubMed Web of Science ®Google Scholar
• Ignatov A, Ignatov T, Roessner A, Costa SD, Kalinski T. Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 2010;123(1):87–96.
   PubMed Web of Science ®Google Scholar
• Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res 2010;70(3):1184–1194.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E. Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006;12(21):6359–6366.
   PubMed Web of Science ®Google Scholar
• Tokuda Y, Suzuku Y, Saito Y, Umemura S. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review. Breast Cancer 2009;16(4):295–300.
   PubMed Web of Science ®Google Scholar
• Kauraniemi P, Hautaniemi S, Autio R, Astola J, Monni O, Elkahloun A, Kallioniemi A. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 2004;23(4):1010–1013.
   PubMed Web of Science ®Google Scholar
• Prossnitz ER, Maggiolini M. Mechanisms of estrogen signalling and gene expression via GPR30. Mol Cell Endocrinol 2009;308(1–2):32–38.
   PubMed Web of Science ®Google Scholar
• Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009;28(5):523–532.
   PubMed Web of Science ®Google Scholar
• Madeo A, Maggiolini M. Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 2010;70(14):6036–6046.
   PubMed Web of Science ®Google Scholar
• Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. Gprotein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Comun 2006; 346(3):904–910.
   PubMed Web of Science ®Google Scholar
• Revankar CM, Cimino DF, Sklar LA, Arteburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signalling. Science 2005;307(5715):1625–1630.
   PubMed Web of Science ®Google Scholar
• Thomas P, Pang Y, Filardo EJ, Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005;146(2):624–632.
   PubMed Web of Science ®Google Scholar
• Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: from discovery to functions in vivo. Endocr J 2010;57(2):101–107.
   PubMed Web of Science ®Google Scholar
• Filardo E, Quinn J, Pang Y, Graber C, Shaw S, Dong J, Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 at the plasma membrane. Endocrinology 2007;48(7):3236–3245.
   Google Scholar
• Pedram A, Razandi M, Levin ER. Nature of functional estrogen receptors at the plasma membrane. Mol Endocrinol 2006;20(9):1996–2009.
   PubMed Web of Science ®Google Scholar
• Madak-Erdogan Z, Kieser KJ, Kim SH, Komm B, Katzenellenbogen JA, Katzenellenbogen BS. Nuclear and extranuclear pathway inputs in the reulation of global gene expression by estrogen receptors. Mol Endocrinol 2008;22(9):2116–2127.
   PubMed Web of Science ®Google Scholar
• Ahola TM, Manninen T, Alkio N, Ylikomi T. G protein-coupled receptor 30 is critical for a progestin-induced growth inhibition in MCF-7 breast cancer cells. Endocrinology 2002; 143(9):3376–3384.
   PubMed Web of Science ®Google Scholar
• Teng J, Wang ZY, Prossnitz ER, Bjorling DE. The G protein-coupled receptor GPR30 inhibits human urothelial cell proliferation. Endocrinology 2008;149(8):4024–4034.
   PubMed Web of Science ®Google Scholar
• Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of ERK1/2, c-jun/c-fos- dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ 2010;17(9):1511–1523.
   PubMed Web of Science ®Google Scholar
• Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca2 +transfer in the control of apoptosis. Oncogene 2008;27(50):6407–6018.
   PubMed Web of Science ®Google Scholar
• Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via transactivation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000;14(10):1649–1660.
   PubMed Web of Science ®Google Scholar
• Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Ando S, Maggiolini M. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha positive cancer cells. Mol Endocrinol 2009;23(11):1815–1826.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li JG, Zheng XY, Jin F, Dong HT. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J (Engl) 2009;122(22):2763–2769.
   PubMed Web of Science ®Google Scholar
• Ignatov A, Ignatov T, Weissenborn C, Eggemann H, Bischoff J, Semczuk A, Roessner A, Costa SD, Kalinski T. G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 2011;128(2):457–466.
   PubMed Web of Science ®Google Scholar
• Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005;41(16): 2449–2461.
   PubMed Web of Science ®Google Scholar
• Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. Cancer Res 1988;48(4):802–805.
   PubMed Web of Science ®Google Scholar
• Basu A, Rowan BG. Genes related to estrogen action in reproduction and breast cancer. Front Biosci 2005;10:2346–2372.
   PubMed Web of Science ®Google Scholar
• Liu J, Liu YG, Huang R, Yao C, Li S, Yang W, Yang D, Huang RP. Concurrent down-regulation of Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer Genomics Proteomics 2007;4(6):377–385.
   PubMedGoogle Scholar
• Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fang M. Early growth response gene 1 is deleted in estrogen receptor-negative human breast carcinoma. Cancer 2005;104(5):925–930.
   PubMed Web of Science ®Google Scholar
• Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, Adamson ED. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumour formation. Int J Cancer 1997;72(1):102–109.
   PubMed Web of Science ®Google Scholar